04:20am Monday 11 December 2017

Cancer’s ability to ‘hijack’ regulatory mechanism increases metastasis

When skyscrapers go up, contractors rely on an infrastructure of steel beams and braces. Some cancers grow the same way, using a biological matrix from which the tumor can thrive and spread.

Scientists at The University of Texas MD Anderson Cancer Center and The University of North Carolina at Chapel Hill (UNC) have found that one component of this human scaffolding called collagen “cross-links” can determine a tumor’s ability to grow and spread. These cross-links of protein complexes enable connective tissue cells known as “stroma” to stiffen, stimulating tumor cell invasion and metastasis.

Study results were published in today’s online edition of the Journal of Clinical Investigation.

Collagen is the most common type of scaffolding protein, contributing to tissue strength. Various aspects of collagen metabolism do not function normally in cancers originating in epithelial tissues and have been an area of intense study.

The MD Anderson/UNC team studied two collagen cross-links, HLCC (hydroxylysine aldehyde-derived collagen cross-links) and LCC (lysine aldehyde-derived collagen cross-links) in mice and human epithelial lung cancer specimens. UNC team member Mitsuo Yamauchi, Ph.D., found that HLCCs are most commonly found in skeletal tissues, while LCCs are normally seen in soft tissues.

Jonathan Kurie, M.D. 

“We observed that tumor stroma had higher amounts of HLCC and lower amounts of LCC than what is found in normal tissue,” said Jonathan Kurie, M.D., professor, Department of Thoracic/Head and Neck Medical Oncology. “Expression of the gene LH2 or lysyl hydroxylase 2 in tumor cells increased the HLCC-to-LCC ratio in tumor stroma and enhanced tumor stiffness leading to metastasis. These findings suggest that the types of collagen cross-links in cancer may play a crucial role in regulating stromal stiffness and determining tumor cell metastatic fate.”

Because LH2 enhances tumor cells’ ability to metastasize, it functions as a regulatory “switch.” Thus, LH2 is able to control the relative abundance of biochemically distinct types of collagen cross-links in the tumor stroma, said Kurie. This finding has therapeutic potential because the enzymatic activity of LH2 might be inhibited selectively with small molecules that bind to LH2.

“Our investigation presented the first evidence that the types of collagen cross-links in tumor stroma are important in determining stromal stiffness and tumor cell metastatic potential,” said Kurie.

MD Anderson study participants included Yulong Chen, Ph.D., Li Sun, Ph.D., Young-Ho Ahn, Ph.D., Daniela Pankova, Ph.D., and Nishan Thilaganathan, Department of Thoracic/Head and Neck Medical Oncology; Jaime Rodriguez, M.D., Hui Liu, Ph.D., Carmen Behrens, M.D., and Ignacio Wistuba, M.D., Department of Translational Molecular Pathology; Chad Creighton, Ph.D., Department of Bioinformatics and Computational Biology; and Tomasz Zal, Ph.D., Department of Immunology. Other participating institutions included the University of North Carolina at Chapel Hill, Chapel Hill, N.C.; Mayo Clinic Cancer Center, Rochester, Minn.; Ewha Woman’s University School of Medicine, Seoul, Korea; Rice University, Houston; Houston Methodist Research Institute; Baylor College of Medicine, Houston; Duke University Medical Center, Durham, N.C.; and The University of Texas Southwestern Medical Center at Dallas.

The study was funded by the National Institutes of Health (RO1 CA109478, CA125123, CA125269, CA157450, AR060978, CA184817-01 and P30 EY007551); the Cancer Prevention Research Institute of Texas (RP120713); the UT Lung Specialized Programs of Research Excellence Grant (P50 CA70907); the Department of Defense (W81XWH-07-1-0306); and the MD Anderson Cancer Center Support Grant (CA016671).

Media Specialist Contact

 

Ron Gilmore
713-745-1898
rlgilmore1@mdanderson.org

MD Anderson Communications Office
713-792-0655


Share on:
or:

Health news